# A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

> **NCT03484520** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 48 (actual)

## Conditions studied

- Cancer - Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Dinaciclib

## Key facts

- **NCT ID:** NCT03484520
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-23
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2022-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03484520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03484520, "A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03484520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*